In a major step forward, the FDA approved the first generic liraglutide for weight loss in August 2025, making these treatments more affordable
The GH response to secretagogues is saturable: beyond a certain point, additional GHRP-2 does not produce proportionally more GH because the pituitarys releasable pool and the receptor system are finite, and somatostatin feedback increasingly opposes release
The reduced food volume makes every bite count more, not less
It is also worth knowing that SheMed launched an active clinical study in December 2024 specifically exploring how GLP-1 medications benefit conditions that disproportionately affect women, including endometriosis
That matters because many of the most common side effects are gastrointestinal and are strongly influenced by how quickly patients escalate their dose
Ohta K, Miki T, Warita K, Suzuki S, Kusaka T, Yakura T, et al